Graft failure, mortality no different for National Kidney Registry, control living donor transplant recipients
WEDNESDAY, Jan. 29, 2020 (HealthDay News) — A nationalized kidney paired donation program results in equivalent outcomes compared with control living kidney donor transplant, according to a study published online Jan. 28 in the Clinical Journal of the American Society of Nephrology.
David B. Leeser, M.D., from East Carolina University in Greenville, North Carolina, and colleagues estimated the risk for death-censored graft failure and mortality among 2,363 National Kidney Registry recipients and 54,497 control kidney transplant recipients.
The researchers found that National Kidney Registry recipients were more likely to be female, African-American, older, and on public insurance. They were also more likely to have a panel of reactive antibodies >80, spend longer on dialysis, and be a previous transplant recipient. During a median follow-up of 3.7 years for National Kidney Registry recipients, they had similar graft failure (5 versus 6 percent; log-rank P = 0.2) and mortality incidence (9 versus 10 percent; log-rank P = 0.4) compared with controls. No detectable difference was seen between National Kidney Registry and control recipients in graft failure (adjusted hazard ratio, 0.95; 95 percent confidence interval, 0.77 to 1.18; P = 0.6) or mortality (adjusted hazard ratio, 0.86; 95 percent confidence interval, 0.70 to 1.07; P = 0.2) after adjustment for donor, recipient, and transplant factors.
“These results should reassure the larger transplant community that a national kidney paired donation program is a safe and effective way to treat patients with incompatible living donors,” the authors write.
One author disclosed financial ties to Sanofi, Novartis, and CSL Behring.
Abstract/Full Text (subscription or payment may be required)
Editorial (subscription or payment may be required)
Copyright © 2020 HealthDay. All rights reserved.
